整合素作为血管及相关疾病的药物靶点
Integrins as Drug Targets in Vascular and Related Diseases.
作者信息
Meredith Emily, Schwartz Martin A
机构信息
Yale Cardiovascular Research Center, Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, Connecticut 06511, USA.
Department of Cell Biology, Yale School of Medicine.
出版信息
Int J Drug Discov Pharm. 2024 Jun;3(2). doi: 10.53941/ijddp.2024.100010. Epub 2024 Jun 21.
Abstract
Integrins are transmembrane receptors that, as critical participants in a vast range of pathological processes, are potential therapeutic targets. However, in only a few cases has the promise been realized by drug approval. In this review, we briefly review basic integrin biology and participation in disease, challenges in the development of safe, effective integrin-targeted therapies, and recent advances that may lead to progress.
摘要
整合素是跨膜受体，作为众多病理过程的关键参与者，是潜在的治疗靶点。然而，只有少数情况下这一前景通过药物获批得以实现。在本综述中，我们简要回顾整合素的基础生物学及其在疾病中的作用、开发安全有效的整合素靶向疗法所面临的挑战，以及可能带来进展的最新研究成果。
相似文献
1
Integrins as Drug Targets in Vascular and Related Diseases.整合素作为血管及相关疾病的药物靶点
Int J Drug Discov Pharm. 2024 Jun;3(2). doi: 10.53941/ijddp.2024.100010. Epub 2024 Jun 21.
2
Integrins in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Opportunities.整合素在心血管健康与疾病中的作用：分子机制与治疗机遇
Biomolecules. 2025 Feb 6;15(2):233. doi: 10.3390/biom15020233.
3
Integrin targeted therapeutics.整合素靶向治疗。
Theranostics. 2011 Feb 17;1:154-88. doi: 10.7150/thno/v01p0154.
4
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.整合素复合物中蛋白-配体相互作用的研究进展：结构测定方面的进展。
J Med Chem. 2020 Jun 11;63(11):5675-5696. doi: 10.1021/acs.jmedchem.9b01869. Epub 2020 Feb 13.
5
Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.肿瘤血管生成中的血管整合素：介质与治疗靶点
Endothelium. 2006 Mar-Apr;13(2):113-35. doi: 10.1080/10623320600698037.
6
Targeting integrin pathways: mechanisms and advances in therapy.靶向整合素途径：机制与治疗进展。
Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6.
7
Integrins in cancer: Emerging mechanisms and therapeutic opportunities.整合素在癌症中的作用：新出现的机制和治疗机会。
Pharmacol Ther. 2023 Jul;247:108458. doi: 10.1016/j.pharmthera.2023.108458. Epub 2023 May 27.
8
Integrins as therapeutic targets: lessons and opportunities.整合素作为治疗靶点：经验与机遇。
Nat Rev Drug Discov. 2010 Oct;9(10):804-20. doi: 10.1038/nrd3266.
9
Integrins as therapeutic targets.整合素作为治疗靶点。
Trends Pharmacol Sci. 2012 Jul;33(7):405-12. doi: 10.1016/j.tips.2012.04.002. Epub 2012 May 25.
10
Integrins: novel therapeutic targets for cardiovascular diseases.整合素：心血管疾病的新型治疗靶点。
Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):109-32. doi: 10.2174/187152507780363223.
引用本文的文献
1
Integrins in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Opportunities.整合素在心血管健康与疾病中的作用：分子机制与治疗机遇
Biomolecules. 2025 Feb 6;15(2):233. doi: 10.3390/biom15020233.
本文引用的文献
1
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing.通过随机的表观基因组编辑实现体内持久而高效的基因沉默。
Nature. 2024 Mar;627(8003):416-423. doi: 10.1038/s41586-024-07087-8. Epub 2024 Feb 28.
2
Family-wide analysis of integrin structures predicted by AlphaFold2.对由AlphaFold2预测的整合素结构进行全家族分析。
Comput Struct Biotechnol J. 2023 Sep 18;21:4497-4507. doi: 10.1016/j.csbj.2023.09.022. eCollection 2023.
3
Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.奥地利纳武单抗相关性进行性多灶性白质脑病的长期预后：一项全国性回顾性研究。
J Neurol. 2024 Jan;271(1):374-385. doi: 10.1007/s00415-023-11924-7. Epub 2023 Sep 20.
4
Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy.进行性多灶性白质脑病患者的长期预后和总死亡率。
Sci Rep. 2023 Aug 31;13(1):14291. doi: 10.1038/s41598-023-41147-9.
5
Challenges in the Development and Application of Organ-on-Chips for Intranasal Drug Delivery Studies.用于鼻内给药研究的器官芯片开发与应用中的挑战。
Pharmaceutics. 2023 May 22;15(5):1557. doi: 10.3390/pharmaceutics15051557.
6
Combined application of biosponges and an antifibrotic agent for the treatment of volumetric muscle loss.生物海绵与抗纤维化剂联合应用治疗容积性肌肉损失。
Am J Physiol Cell Physiol. 2023 Jun 1;324(6):C1341-C1352. doi: 10.1152/ajpcell.00092.2023. Epub 2023 May 15.
7
Advanced pathophysiology mimicking lung models for accelerated drug discovery.用于加速药物研发的模拟肺部模型的高级病理生理学
Biomater Res. 2023 Apr 26;27(1):35. doi: 10.1186/s40824-023-00366-x.
8
Lineage-Specific Induced Pluripotent Stem Cell-Derived Smooth Muscle Cell Modeling Predicts Integrin Alpha-V Antagonism Reduces Aortic Root Aneurysm Formation in Marfan Syndrome Mice.谱系特异性诱导多能干细胞衍生平滑肌细胞建模预测整合素 α-V 拮抗作用可减少马凡综合征小鼠的主动脉根部动脉瘤形成。
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1134-1153. doi: 10.1161/ATVBAHA.122.318448. Epub 2023 Apr 20.
9
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).在奥地利的那他珠单抗实际应用：来自奥地利多发性硬化症治疗注册研究（AMSTR）的数据。
J Neurol. 2023 Aug;270(8):3779-3786. doi: 10.1007/s00415-023-11686-2. Epub 2023 Apr 19.
10
FN (Fibronectin)-Integrin α5 Signaling Promotes Thoracic Aortic Aneurysm in a Mouse Model of Marfan Syndrome.FN（纤连蛋白）-整联蛋白 α5 信号促进马凡综合征小鼠模型的胸主动脉瘤。
Arterioscler Thromb Vasc Biol. 2023 May;43(5):e132-e150. doi: 10.1161/ATVBAHA.123.319120. Epub 2023 Mar 30.
Zotero 插件